Last updated: May 31, 2026
Suppliers for “AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)” drug product: Who co-packages and manufactures?
No supplier list can be produced from the provided product name alone. The term “AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)” is not a recognized active ingredient, INN, brand name, or FDA/Orange Book listing identifier in the information provided, so co-manufacturing and co-packing suppliers cannot be verified to a specific drug, dosage form, strength, labeler, NDC, application, or jurisdiction.
What does “AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)” refer to in pharma supply chains?
A valid supplier analysis requires a traceable product identity (at minimum: active ingredient(s), dosage form, strength, labeler/NDC, or marketing authorization holder). Without that, “co-pack (copackaged)” could describe any of the following, each with different supplier ecosystems:
- Primary manufacturer of finished dosage form (tablet/capsule/suspension/sterile product)
- Contract manufacturer of drug substance versus contract manufacturer of drug product
- Co-packer for secondary packaging, kitting, labeling, and distribution sets
- 3PL/fulfillment partner acting as packager-of-record
- Distributor labeler who holds the product under an authorization while outsourcing filling and packaging
Which companies supply co-pack and kitting services for “copackaged” pharmaceutical products?
Co-pack supply chains typically split across roles:
- Co-packer: secondary packaging, carton/label application, kit assembly, tamper-evidence integration
- Contract manufacturer: bulk filling, bottling/blistering, line clearance, stability programs
- Packaging material suppliers: bottles, blisters, cartons, leaflets, labels, serialization components
- QA release and regulatory compliance vendors: QP release support, batch record services
- Sterile supply chain (if applicable): aseptic fill-finish and cleanroom manufacturing services
A supplier list cannot be mapped to this product name without a definable product identity.
What suppliers handle drug product manufacturing versus secondary packaging for copackaged medicines?
For “copackaged” finished goods, suppliers are usually segregated as:
- Drug product manufacturer (DP): produces finished dosage form and primary packaging
- Co-packer (CP): performs secondary packaging and may add accessories, device components, or promotional materials
- Labeler/distributor: may be separate from DP and CP and can change without altering the underlying dosage form
No supplier ranking can be created because “AVMAPKI FAKZYNJA” does not identify a trackable DP/CP product.
What patents or Orange Book entries can confirm the labeled product identity and supplier-of-record?
Supplier-of-record mapping usually uses:
- FDA Orange Book to anchor the NDA/ANDA and active ingredient
- NDC Directory or labeler listing to identify the applicant/labeler and often the manufacturing site
- Corresponding Chemistry, Manufacturing, and Controls (CMC) listings to map plants
The product name provided does not include the NDA/ANDA number, active ingredient, or NDC, so patent and listing-based confirmation cannot be completed.
How to find co-pack suppliers for a specific copackaged drug in the real world (NDC, labeler, and application)?
In practice, sourcing requires:
- NDC lookup (labeler, manufacturer, packager)
- Application linkage (NDA/ANDA/BLA) to connect manufacturing sites to regulatory submissions
- Confirmation via inspection history (FDA establishment listings) and GMP certificate coverage (by jurisdiction)
- Contract responsibility mapping (co-packing agreement, DMF/CMC references, and site-specific batch release roles)
No NDC or application identifier is provided, so supplier identification cannot be performed.
What generic entry risks exist for copackaged products like this, and does that change suppliers?
Supplier lists for generics can differ because:
- New ANDA holders select different DP sites
- Co-pack arrangements change based on distribution model and procurement
- Labelers and packager-of-record can switch even when the dosage form matches
Because the referenced product cannot be tied to an active ingredient or application, supplier and competitive risk mapping is not executable.
Key Takeaways
- A supplier list for “AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)” cannot be produced without a verifiable product identity (active ingredient/dosage form/strength plus NDA/ANDA or NDC).
- “Copackaged” describes packaging and kitting responsibilities, not a unique drug product, so suppliers vary by contract structure and regulatory labeler.
FAQs
- How do I identify the co-packer for a copackaged pharmaceutical when only an internal product name is available?
- Does the labeler-of-record on an NDC always equal the contract manufacturer or co-packer?
- What FDA sources are used to map a drug product to its manufacturing and packaging establishments?
- When a product is copackaged, who typically holds batch release responsibilities and QP/QA sign-off?
- Can a change in packaging format or kit contents shift the co-pack supplier without changing the drug application?
References
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
- FDA. (n.d.). NDC Directory. U.S. Food and Drug Administration.
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
